Physician

Internal Medicine

Dr. Carl C. Peck, MD

Dr. Carl C. Peck works in the field of Internal Medicine. He attended University of Kansas School of Medicine. Carl Peck is also a published doctor. He has 49 paper published. The most recent paper is: Pharmacodynamics of temazepam in primary insomnia: assessment of the value of quantitative electroencephalography and saccadic eye movements in predicting improvement ...

Publications

Quantitative clinical pharmacology is transforming drug regulation.
A roadmap for biomarker qualification.
Population pharmacokinetic analysis and simulation of the time-concentration profile of etanercept in pediatric patients with juvenile rheumatoid arthritis.
Evidence of effectiveness: how much can we extrapolate from existing studies?
Randomized concentration-controlled trials: motivations, use, and limitations.
Hypothesis: a single clinical trial plus causal evidence of effectiveness is sufficient for drug approval.
Population pharmacokinetic and pharmacodynamic modeling of etanercept using logistic regression analysis.
Transcutaneous chemical collection of caffeine in normal subjects: relationship to area under the plasma concentration-time curve and sweat production.
An evaluation of the integration of pharmacokinetic and pharmacodynamic principles in clinical drug development. Experience within Hoffmann La Roche.
Continuous transepidermal drug collection: basis for use in assessing drug intake and pharmacokinetics.
Dog mastocytoma cells produce transforming growth factor beta 1.
Pharmacokinetic rationale for a malarial suppressant administered once monthly.
Biological sex analysis in clinical research.
A pharmacodynamic Markov mixed-effects model for the effect of temazepam on sleep.
Transcutaneous theophylline collection in preterm infants.
Current status of clinical pharmacology training in the United States.
Adaptive control with feedback strategies for suramin dosing.
Physiologically based pharmacokinetics in drug development and regulatory science: a workshop report (Georgetown University, Washington, DC, May 29-30, 2002).
Physiologically-based pharmacokinetics in drug development and regulatory science.
Improved computer-assisted digoxin therapy. A method using feedback of measured serum digoxin concentrations.
Pharmacokinetics and pharmacodynamics of 1,25-dihydroxyvitamin D3 in the chick.
Computer-assisted digoxin therapy.
Bayesian regression analysis of non-steady-state phenytoin concentrations: evaluation of predictive performance.
Clinical utility of a Bayesian dosing program for phenytoin.
Evaluation of a Bayesian regression-analysis computer program for predicting phenytoin concentration.
Opportunities for integration of pharmacokinetics, pharmacodynamics, and toxicokinetics in rational drug development.
The randomized concentration-controlled trial: an evaluation of its sample size efficiency.
Dr Marcus M. Reidenberg, recipient of the 1999 Harry Gold Award.
Pharmacodynamics of temazepam in primary insomnia: assessment of the value of quantitative electroencephalography and saccadic eye movements in predicting improvement ...
Understanding comparisons of drug introductions between the United States and the United Kingdom.
Differences in serum digoxin concentrations between outpatients and inpatients: an effect of compliance?
The problem of choosing weights in nonlinear regression analysis of pharmacokinetic data.
Extended least squares nonlinear regression: a possible solution to the "choice of weights" problem in analysis of individual pharmacokinetic data.
Determinants of the renal clearance of digoxin.
Drug development: improving the process.
Preventing postmarketing changes in recommended doses and marketing withdrawals.
Clinical assessment of a two-compartment Bayesian forecasting method for lidocaine.
Simulation of clinical trials.
Assessment and reporting of clinical pharmacology information in drug labeling.
Optimizing the science of drug development: opportunities for better candidate selection and accelerated evaluation in humans.
Integration of pharmacokinetic and pharmacodynamic studies in the discovery, development, and review of protein therapeutic agents: a conference report.
"Getting the dose right": facts, a blueprint, and encouragements.
Clinical pharmacology training at the Food & Drug Administration.
Postmarketing drug dosage changes of 499 FDA-approved new molecular entities, 1980-1999.
Prediction of the outcome of a phase 3 clinical trial of an antischizophrenic agent (quetiapine fumarate) by simulation with a population pharmacokinetic and pharmacod...
Postmarketing drug dosage changes.
Simulation of correlated continuous and categorical variables using a single multivariate distribution.
Recommended changes to oncology clinical trial design: revolution or evolution?

Schools

University of Kansas School of Medicine

Doctors Specialties

Internal Medicine

Accepted Insurances

Education

UCSF
Tripler Army Medical Center
University of Kansas School of Medicine

Helpful Reviews

Give Anonymous Review

Similar Doctors

	Dr. Margaret C. McKee, MD This Doctor is OpenDoctor Recommended.
	Dr. Cristina Valero, MD This Doctor is OpenDoctor Recommended.
	Dr. David Javitz, MD This Doctor is OpenDoctor Recommended.
	Dr. David L. Harris, MD
	Dr. Ann L. Bollay, MD This Doctor is OpenDoctor Recommended.
	Dr. Thomas Najarian, MD This Doctor is OpenDoctor Recommended.
	Dr. Camilo S. Guiang, MD
	Dr. Rodolfo C. Castillo-Ruiz, MD
	Dr. William S. Sogaard, MD This Doctor is OpenDoctor Recommended.
	Dr. Bruce Faecher, MD